These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26027402)

  • 1. [Angiogenesis and its association with inflammation and fibrosis in course of the development of scleroderma systematica].
    Radenska-Lopovok SG; Korzenyova EG; Alekperov RT
    Arkh Patol; 2015; 77(2):56-60. PubMed ID: 26027402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis.
    Koch AE; Distler O
    Arthritis Res Ther; 2007; 9 Suppl 2(Suppl 2):S3. PubMed ID: 17767741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis.
    Manetti M; Guiducci S; Ibba-Manneschi L; Matucci-Cerinic M
    J Cell Mol Med; 2010 Jun; 14(6A):1241-54. PubMed ID: 20132409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scleroderma dermal microvascular endothelial cells exhibit defective response to pro-angiogenic chemokines.
    Tsou PS; Rabquer BJ; Ohara RA; Stinson WA; Campbell PL; Amin MA; Balogh B; Zakhem G; Renauer PA; Lozier A; Arasu E; Haines GK; Kahaleh B; Schiopu E; Khanna D; Koch AE
    Rheumatology (Oxford); 2016 Apr; 55(4):745-54. PubMed ID: 26705326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dermal dendritic cell population and blood vessels are diminished in the skin of systemic sclerosis patients: relationship with fibrosis degree and disease duration.
    de-Sá-Earp AP; do Nascimento AP; Carneiro SC; Porto LC; Monte-Alto-Costa A
    Am J Dermatopathol; 2013 Jun; 35(4):438-44. PubMed ID: 23262669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers.
    Distler O; Del Rosso A; Giacomelli R; Cipriani P; Conforti ML; Guiducci S; Gay RE; Michel BA; Brühlmann P; Müller-Ladner U; Gay S; Matucci-Cerinic M
    Arthritis Res; 2002; 4(6):R11. PubMed ID: 12453314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenic cytokines and growth factors in systemic sclerosis.
    Liakouli V; Cipriani P; Marrelli A; Alvaro S; Ruscitti P; Giacomelli R
    Autoimmun Rev; 2011 Aug; 10(10):590-4. PubMed ID: 21549861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular players in angiogenesis during the course of systemic sclerosis.
    Cipriani P; Marrelli A; Liakouli V; Di Benedetto P; Giacomelli R
    Autoimmun Rev; 2011 Aug; 10(10):641-6. PubMed ID: 21549220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pathology of scleroderma vascular disease.
    Fleming JN; Schwartz SM
    Rheum Dis Clin North Am; 2008 Feb; 34(1):41-55; vi. PubMed ID: 18329531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnostic value of the determination of angiogenic factors and cytokine composition parameters in the serum and urine of patients with scleroderma systematica].
    Rebrov AP; Patrikeeva DA; Zakharova NB; Karpova OG; Oksen'chuk AN
    Ter Arkh; 2014; 86(5):18-25. PubMed ID: 25026798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis.
    Maurer B; Distler A; Suliman YA; Gay RE; Michel BA; Gay S; Distler JH; Distler O
    Ann Rheum Dis; 2014 Oct; 73(10):1880-7. PubMed ID: 23918036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired angiogenesis in systemic sclerosis: the emerging role of the antiangiogenic VEGF(165)b splice variant.
    Manetti M; Guiducci S; Ibba-Manneschi L; Matucci-Cerinic M
    Trends Cardiovasc Med; 2011 Oct; 21(7):204-10. PubMed ID: 22867700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for reduced angiogenesis in bone marrow in SSc: immunohistochemistry and multiparametric computerized imaging analysis.
    Carrai V; Miniati I; Guiducci S; Capaccioli G; Alterini R; Saccardi R; Conforti ML; Rigacci L; Rotunno G; Bosi A; Cerinic MM
    Rheumatology (Oxford); 2012 Jun; 51(6):1042-8. PubMed ID: 22271757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tumor necrosis factor alpha in systemic scleroderma].
    Alekperov RT; Timchenko AV; Nasonov EL
    Klin Med (Mosk); 2003; 81(12):4-7. PubMed ID: 14971148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
    Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E
    Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Morphological characteristics of sclerodermic angiopathy].
    Alekperov RT; Radenska-Lopovok SG; Guseva NG
    Arkh Patol; 2004; 66(6):42-6. PubMed ID: 15648167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis.
    Distler O; Distler JH; Scheid A; Acker T; Hirth A; Rethage J; Michel BA; Gay RE; Müller-Ladner U; Matucci-Cerinic M; Plate KH; Gassmann M; Gay S
    Circ Res; 2004 Jul; 95(1):109-16. PubMed ID: 15178641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor and basic fibroblast growth factor expression positively correlates with angiogenesis and peritumoural brain oedema in astrocytoma.
    Jang FF; Wei W; De WM
    J Ayub Med Coll Abbottabad; 2008; 20(2):105-9. PubMed ID: 19385471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis.
    Beon M; Harley RA; Wessels A; Silver RM; Ludwicka-Bradley A
    Clin Exp Rheumatol; 2004; 22(6):733-42. PubMed ID: 15638048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Protective Effects of Bevacizumab in Bleomycin-Induced Experimental Scleroderma.
    Koca SS; Ozgen M; Dagli AF; Gozel N; Ozercan IH; Isik A
    Adv Clin Exp Med; 2016; 25(2):249-53. PubMed ID: 27627557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.